Mariam Hanna1, Lauren Beth Strober2. 1. Montclair State University, USA. 2. Kessler Foundation, West Orange, NJ, USA; Rutgers, the State University of New Jersey, New Jersey Medical School, Department of Physical Medicine and Rehabilitation, USA. Electronic address: lstrober@kesslerfoundation.org.
Abstract
BACKGROUND: Individuals with multiple sclerosis (MS) are often plagued by the unpredictability of their disease and have to contend with uncertainty in their life and significant life changes. This can lead to high levels of stress, perceived lack of control, helplessness, and anxiety. Despite these circumstances, anxiety disorders are often overshadowed by depression, which can result in its presence being overlooked and undertreated by many medical professionals. METHODS: One hundred and eighty three individuals with MS completed a comprehensive online survey assessing depression and anxiety and the demographic and disease risk factors of such, including social support and substance use. Participants also completed measures of MS symptomatology, disease management, psychological well-being, and quality of life to determine the impact of depression and anxiety on outcomes associated with MS. RESULTS: Findings suggest that both depression and anxiety are prevalent in MS and related to many outcomes. However, based on comparisons of the associations and group comparisons, with a few exceptions, anxiety proved to more impactful than depression when examining these outcomes. When evaluating the risk factors/contributors of anxiety and depression, social support was a consistent predictor. Younger age and shorter disease duration were also associated with anxiety, while lower education and substance use were predictors of depression. CONCLUSION: Findings suggest that attention to anxiety be given as much as depression as it plays a large role in individuals' perceived health and well-being, which subsequently impacts the severity of symptoms and overall quality of life. Early identification of anxiety and potential substance use and increased social support also appear to be crucial for mitigating the impact of depression and anxiety.
BACKGROUND: Individuals with multiple sclerosis (MS) are often plagued by the unpredictability of their disease and have to contend with uncertainty in their life and significant life changes. This can lead to high levels of stress, perceived lack of control, helplessness, and anxiety. Despite these circumstances, anxiety disorders are often overshadowed by depression, which can result in its presence being overlooked and undertreated by many medical professionals. METHODS: One hundred and eighty three individuals with MS completed a comprehensive online survey assessing depression and anxiety and the demographic and disease risk factors of such, including social support and substance use. Participants also completed measures of MS symptomatology, disease management, psychological well-being, and quality of life to determine the impact of depression and anxiety on outcomes associated with MS. RESULTS: Findings suggest that both depression and anxiety are prevalent in MS and related to many outcomes. However, based on comparisons of the associations and group comparisons, with a few exceptions, anxiety proved to more impactful than depression when examining these outcomes. When evaluating the risk factors/contributors of anxiety and depression, social support was a consistent predictor. Younger age and shorter disease duration were also associated with anxiety, while lower education and substance use were predictors of depression. CONCLUSION: Findings suggest that attention to anxiety be given as much as depression as it plays a large role in individuals' perceived health and well-being, which subsequently impacts the severity of symptoms and overall quality of life. Early identification of anxiety and potential substance use and increased social support also appear to be crucial for mitigating the impact of depression and anxiety.
Authors: Aaron P Turner; Rhonda M Williams; James D Bowen; Daniel R Kivlahan; Jodie K Haselkorn Journal: Arch Phys Med Rehabil Date: 2006-08 Impact factor: 3.966
Authors: Rosa E Boeschoten; Annemarie M J Braamse; Aartjan T F Beekman; Pim Cuijpers; Patricia van Oppen; Joost Dekker; Bernard M J Uitdehaag Journal: J Neurol Sci Date: 2016-11-30 Impact factor: 3.181
Authors: K M Scott; R Bruffaerts; A Tsang; J Ormel; J Alonso; M C Angermeyer; C Benjet; E Bromet; G de Girolamo; R de Graaf; I Gasquet; O Gureje; J M Haro; Y He; R C Kessler; D Levinson; Z N Mneimneh; M A Oakley Browne; J Posada-Villa; D J Stein; T Takeshima; M Von Korff Journal: J Affect Disord Date: 2007-02-09 Impact factor: 4.839
Authors: A G Beiske; E Svensson; I Sandanger; B Czujko; E D Pedersen; J H Aarseth; K M Myhr Journal: Eur J Neurol Date: 2008-01-22 Impact factor: 6.089
Authors: Małgorzata Szcześniak; Andrzej Potemkowski; Waldemar Brola; Zdzisław Kroplewski; Roman Ryszard Szałachowski; Marek Zak; Maciej Wilski; Piotr Sobolewski; Halina Bartosik-Psujek; Katarzyna Kapica-Topczewska; Joanna Tarasiuk; Agata Czarnowska; Alina Kułakowska; Beata Zakrzewska-Pniewska; Katarzyna Kubicka-Bączyk; Natalia Morawiec; Monika Adamczyk-Sowa; Adam Stępień; Jacek Zaborski; Anna Ratajczak; Marcin Ratajczak Journal: Int J Environ Res Public Health Date: 2022-04-29 Impact factor: 4.614